-
Product Insights
NewNet Present Value Model: BiomX Inc’s BX-004
Empower your strategies with our Net Present Value Model: BiomX Inc's BX-004 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewResistant Pseudomonas aeruginosa Infections – Drugs In Development, 2024
Empower your strategies with our Resistant Pseudomonas aeruginosa Infections – Drugs In Development, 2024 report and make more profitable business decisions. Pseudomonas aeruginosa has become an important cause of infection, especially in patients with compromised host defense mechanisms. It has an ability to rapidly develop resistance to multiple classes of antibiotics. It is the most common pathogen isolated from patients who have been hospitalized for more than one week. Signs and symptoms include pneumonia, fever, fatigue, itchy rash, bleeding ulcers, and...
-
Product Insights
NewCystic Fibrosis – Drugs In Development, 2024
Empower your strategies with our Cystic Fibrosis – Drugs In Development, 2024 report and make more profitable business decisions. Cystic fibrosis (CF) is an inherited disease that causes mucus to build up and clog some of the body’s organs, particularly the lungs and pancreas. Cystic fibrosis affects the cells that produce mucus, sweat and digestive juices. Symptoms include wheezing, breathlessness, repeated lung infections, inflamed nasal passages or a stuffy nose, and severe constipation. Risk factors include family history and race (Northern...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRT-1419 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PRT-1419 in Solid Tumor Drug Details: PRT-1419 is under development for the treatment of solid...
-
Product Insights
Net Present Value Model: Sanofi’s Fitusiran
Empower your strategies with our Net Present Value Model: Sanofi's Fitusiran report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (LAI-287 + Semaglutide) in Type 2 Diabetes
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. (LAI-287 + Semaglutide) in Type 2 Diabetes Drug Details: A fixed dose combination of GLP-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AV-7909 in Anthrax
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AV-7909 in Anthrax report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AV-7909 in Anthrax Drug Details: AV-7909 (NuThrax) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BX-004 in Resistant Pseudomonas aeruginosa Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BX-004 in Resistant Pseudomonas aeruginosa Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.BX-004 in Resistant Pseudomonas aeruginosa InfectionsDrug Details:BX-004 is under development for...
-
Product Insights
Inflammatory Disease Markers Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Inflammatory Disease Markers Pipeline Market Report Overview Inflammatory Disease Markers are antigens/antibodies that detect specific antigens/antibodies produced by bone, cartilage, or any other inflammatory disease activity. The Inflammatory Disease Markers pipeline market research report provides comprehensive information about the inflammatory disease markers pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials that are in progress. Key Segments ·       Anti-Cyclic Citrullinated Peptide Antibody (Anti-CCP) Analyzer Tests ·       C-Reactive Protein (CRP)...